{"preliminary_commentary":{"by_channel":{"x_thread":4,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"IDeate-PanTumor01","nct_id":"NCT04145622","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ideate-pantumor01-nct04145622. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with advanced solid tumors who received I-DXd IV Q3W monotherapy during dose escalation phase. Enrollment to this phase is currently closed.","label":"Dose escalation","type":"EXPERIMENTAL"},{"description":"Currently enrolling participants with advanced solid tumors who will receive I-DXd IV Q3W monotherapy at the recommended dose for expansion.","label":"Dose expansion","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC"],"completion_date":{"date":"2029-10-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor","Malignant Solid Tumor"],"enrollment":{"count":247,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Ifinatamab deruxtecan (I-DXd)","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-06","lead_sponsor":"Daiichi Sankyo","official_title":"Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Evaluate the incidence of dose-limiting toxicities (DLTs)","timeFrame":"Day 1 to Day 21 in Cycle 1 in the dose escalation part"},{"measure":"Evaluate the incidence of adverse events (AEs)","timeFrame":"Cycle 1 Day 1 through disease progression within 8 cycles (each cycle is 21 days)"},{"measure":"Investigate the antitumor activity of ifinatamab deruxtecan (I-DXd)","timeFrame":"Cycle 1 Day 1 through disease progression within 8 cycles (each cycle is 21 days)"}],"references":[{"citation":"Johnson ML, Patel MR, Falchook GS, Koyama T, Gutierrez M, Awad MM, Piha-Paul SA, Friedman CF, Satoh T, Okamoto N, Singh J, Yoshizuka N, Windish HP, Qian M, Tran BP, Doi T. Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. Lancet Oncol. 2026 Apr;27(4):491-501. doi: 10.1016/S1470-2045(25)00733-8.","pmid":"41926962","type":"DERIVED"}],"start_date":{"date":"2019-11-03","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors","url":"https://clinicaltrials.gov/study/NCT04145622"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ideate-pantumor01-nct04145622"}